Ocugen licenses OCU400 rights for $255 million

• Ocugen (NASDAQ:OCGN) granted Roots Pharmaceutical exclusive regional rights to OCU400 for retinitis pigmentosa in the Middle East and North Africa.
• The agreement includes potential sales milestones of up to $255 million, along with royalties of 22% on OCU400 net sales generated by Roots.
• Ocugen said OCU400 remains in Phase 3 development, with topline trial results expected in the first quarter of 2027.

Ocugen (NASDAQ:OCGN) entered an agreement granting Roots Pharmaceutical exclusive regional rights to OCU400, an investigational gene therapy for retinitis pigmentosa, an inherited vision-loss disease.

The agreement, involving Roots’ partner Al-Dhow International Holding, covers commercialization rights across the Middle East and North Africa region.

Under the agreement terms, Ocugen may receive an upfront license fee, potential initial development milestone payments totaling up to $4 million, sales milestones of up to $255 million, and royalties equal to 22% of OCU400 net sales generated by Roots.

Ocugen is advancing OCU400 through the Phase 3 liMeliGhT trial and expects topline results in the first quarter of 2027 before planned regulatory submissions in the United States and Europe.

Ocugen develops gene and cell therapies focused on rare diseases, including treatments designed for inherited eye disorders and other medical conditions.